{"slug":"regeneron-pharmaceuticals","name":"리제네론","name_en":"Regeneron Pharmaceuticals","ticker":"REGN","updated_at":"2026-07-11T10:15:30.805+00:00","canonical":"https://valuechain.wiki/regeneron-pharmaceuticals","kicker":"헬스케어 · S&P 500","kicker_en":"Health Care · S&P 500","lead":"리제네론은 안과 질환 치료제 아일리아와 면역항암제 등을 개발하는 미국의 대형 바이오제약 기업이다. S&P 500 구성종목. 섹터: 헬스케어(Biotechnology). 밸류체인 관계·수치 데이터는 조사 전인 기본 노드로, AI 질문 수요가 관측되면 상세 노드로 승격된다.","lead_en":"Regeneron is a large US biopharma company developing drugs such as the eye treatment Eylea and immuno-oncology therapies. S&P 500 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.","segments":{"parts":[{"name":"자체 의약품 매출"},{"name":"협업 매출(Dupixent 등)"}],"total":"약 $14.2B (FY2024)"},"segments_en":{"parts":[{"name":"Net Product Sales"},{"name":"Collaboration Revenue"}],"total":"approx. $14.2B (FY2024)"},"returns_yearly":{"2021":30.7,"2022":14.2,"2023":21.7,"2024":-18.9,"2025":9,"2026":-13.7},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[],"analysis":null,"analysis_en":null,"analysis_asof":null},"edges":[]}